I would like to think so.
Realistically more positive research updates and announcements on progress on next steps to future revenue would likely correlate to SP momentum then decline in Covid19 cases here.
Interesting how we have the CE Mark granted which was the main topic or concern for shareholders and now we have increased arguments put about quality of their medical technology. Seems contrary to a robust regulatory process in addition to definitive progress made with two reputable authorities in FDA & BSI. Just saying...
Ann: Oncosil breakthrough device receives CE Marking approval, page-116
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.23 |
Change
0.210(20.6%) |
Mkt cap ! $17.49M | |||
| Open | High | Low | Value | Volume |
| $1.05 | $1.24 | $1.03 | $200.2K | 169.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3500 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.25 | 60000 | 1 |
View Market Depth
| Last trade - 16.10pm 26/06/2025 (20 minute delay) ? |
| OSL (ASX) Chart |